MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $40.5 million in its third quarter.
The Madison, Wisconsin-based company said it had a loss of 31 cents per share.
The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 41 cents per share.
The molecular diagnostics company posted revenue of $218.8 million in the period, also beating Street forecasts. Six analysts surveyed by Zacks expected $215.5 million.
Exact Sciences expects full-year revenue in the range of $802 million to $810 million.
Exact Sciences shares have increased 44% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $90.61, an increase of 47% in the last 12 months.